Long-acting beta-adrenoceptor agonist

Nov 28, 2017

Theravance Biopharma Highlights Submission of Landmark IMPACT Data to FDA to Support Expanded Label for Trelegy Ellipta

Nov 16, 2017

Theravance Biopharma Highlights Marketing Authorization in Europe for Trelegy Ellipta as Once-Daily Single Inhaler Triple Therapy for the Treatment of COPD

Sep 20, 2017

Theravance Biopharma Highlights Positive Headline Results from IMPACT Study of Trelegy Ellipta Announced by GlaxoSmithKline and Innoviva

Sep 19, 2017

Theravance Biopharma Highlights Approval of Trelegy Ellipta (Closed Triple) as the First Once-Daily Single Inhaler Triple Therapy for the Treatment of Appropriate Patients with COPD in the US

Sep 18, 2017

Trelegy Ellipta approved as the first once-daily single inhaler triple therapy for the treatment of appropriate patients with COPD in the US

Sep 18, 2017

Theravance Biopharma Highlights GlaxoSmithKline and Innoviva's Receipt of Positive Opinion from CHMP in Europe for Trelegy Ellipta (Closed Triple)

Sep 06, 2017

Tezepelumab Significantly Reduced Asthma Exacerbations For A Broad Population Of Patients With Severe Uncontrolled Asthma